Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial

…, J Siegel, A Jahreis, CP Denton, E Lucero… - The Lancet …, 2020 - thelancet.com
Background A phase 2 trial of tocilizumab showed preliminary evidence of efficacy in systemic
sclerosis. We assessed skin fibrosis and systemic sclerosis-associated interstitial lung …

[HTML][HTML] Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen‐week results from a phase III randomized, double‐blind …

…, SH Lee, R Lidman, J Loveless, E Lucero… - Arthritis & …, 2019 - Wiley Online Library
Objective To investigate the efficacy and safety of ixekizumab in patients with active radiographic
axial spondyloarthritis (SpA) and prior inadequate response to or intolerance of 1 or 2 …

Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial

…, P Rahman, F Ariel, A Berman, J Carrio, E Lucero… - The Lancet, 2020 - thelancet.com
Background Ixekizumab, a high-affinity interleukin-17A (IL-17A) monoclonal antibody, has
previously shown efficacy in radiographic axial spondyloarthritis (also known as ankylosing …

Prevalence of rheumatoid arthritis in Tucumán, Argentina.

A Spindler, V Bellomio, A Berman, E Lucero… - The Journal of …, 2002 - jrheum.org
OBJECTIVE: To ascertain the prevalence of rheumatoid arthritis (RA) in Tucumán, Argentina.
METHODS: The study was conducted between January 1, 1998, and December 31, 1999, …

Validation and crosscultural adaptation of an Argentine Spanish version of the Health Assessment Questionnaire disability index

…, MA Goñi, A Spindler, E Lucero… - JCR: Journal of …, 2004 - journals.lww.com
Background: The Health Assessment Questionnaire (HAQ) is one of the most frequently
used instruments to assess functional capacity in activities of daily living. Objective: The …

Accrual of organ damage over time in Argentine patients with systemic lupus erythematosus: a multi-centre study

…, S Roverano, S Paira, V Bellomio, E Lucero… - Clinical …, 2007 - Springer
The goals of this study were to ascertain damage in patients with systemic lupus erythematosus
(SLE) from five rheumatologic centres in Argentina and to examine overall damage, …

Factors associated with disability in patients with rheumatoid arthritis

…, OL Rillo, V Bellomio, E Lucero… - JCR: Journal of …, 2010 - journals.lww.com
Objective: Analyze disability determinants in a cohort of Argentine patients with rheumatoid
arthritis (RA). Material and Methods: Consecutive patients with RA, according to ACR'87 …

Prevalence and incidence of systemic lupus erythematosus in Tucumán, Argentina

L Gonzalez Lucero, AL Barbaglia, VI Bellomio… - Lupus, 2020 - journals.sagepub.com
The aim of this study was to determine the prevalence and incidence of Systemic Lupus
Erythematosus (SLE) in Tucumán, Argentina. Methods: The study included inpatient and …

Validation and adaptation of the Spanish version of the systemic lupus activity questionnaire (S-SLAQ) in an Argentinean population

…, L Gonzalez Lucero, E Lucero… - Lupus, 2021 - journals.sagepub.com
Objectives To validate the systemic lupus activity questionnaire (SLAQ) in Spanish language.
Methods The SLAQ questionnaire was translated and adapted in Spanish. Consecutive …

FRI0152 Active therapeutic immunization with TNF-kinoid in rheumatoid arthritis patients with secondary resistance to tnfα antagonists is safe and immunogenic

…, B Fautrel, X Mariette, P Sokalov, E Lucero… - Annals of the …, 2013 - ard.bmj.com
Background Blocking TNF alpha (TNFα) with monoclonal antibodies (mAbs) has been
successful in the treatment of rheumatoid arthritis. However primary and secondary resistances …